Identification

Name
Desvenlafaxine
Accession Number
DB06700
Type
Small Molecule
Groups
Approved
Description

Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin-norepinephrine reuptake inhibitor (SNRI class). Desvenlafaxine may be used to treat major depressive disorder and is being studied for use in the management of vasomotor symptoms in postmenopausal women. It is formulated as an extended release tablet. FDA approved in 2008.

Structure
Thumb
Synonyms
  • Desvenlafaxine
  • O-desmethylvenlafaxine
  • ODV
Product Ingredients
IngredientUNIICASInChI Key
Desvenlafaxine fumarateATX24E9M6L93414-04-1SQTJDJZCPOSWSC-WLHGVMLRSA-N
Desvenlafaxine fumarate monohydrateR5JHD7L72A313471-75-9YETWCSLOYUZBLK-JITBQSAISA-N
Desvenlafaxine succinateZB22ENF0XR386750-22-7ORUUBRMVQCKYHB-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DesvenlafaxineTablet, extended release100 mg/1OralSun Pharma Global FZE2014-01-302017-02-08Us
DesvenlafaxineTablet, extended release100 mg/1OralSun Pharmaceutical Industries Limited2013-03-05Not applicableUs63304 0192 30 nlmimage10 9544ca96
DesvenlafaxineTablet, extended release50 mg/1OralSun Pharma Global FZE2014-01-302017-02-08Us
DesvenlafaxineTablet, extended release50 mg/1OralSun Pharmaceutical Industries Limited2013-03-05Not applicableUs63304 0191 30 nlmimage10 aa405562
Desvenlafaxine Extended-releaseTablet, extended release100 mg/1OralMacoven Pharmaceuticals2013-07-10Not applicableUs
Desvenlafaxine Extended-releaseTablet, extended release50 mg/1OralMacoven Pharmaceuticals2013-07-10Not applicableUs
Desvenlafaxine SuccinateTablet, extended release50 mg/1OralGreenstone, Llc2017-03-01Not applicableUs
Desvenlafaxine SuccinateTablet, extended release25 mg/1OralGreenstone, Llc2017-03-01Not applicableUs
Desvenlafaxine SuccinateTablet, extended release100 mg/1OralGreenstone, Llc2017-03-01Not applicableUs
Khedezla Extended-releaseTablet, extended release50 mg/1OralPernix Therapeutics2013-07-10Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-desvenlafaxineTablet, extended release100 mgOralApotex Corporation2017-10-20Not applicableCanada
Apo-desvenlafaxineTablet, extended release50 mgOralApotex Corporation2017-10-20Not applicableCanada
DesvenlafaxineTablet, film coated, extended release50 mg/1OralMylan Pharmaceuticals2017-03-01Not applicableUs
DesvenlafaxineTablet, extended release50 mg/1OralActavis Pharma Company2017-03-01Not applicableUs
DesvenlafaxineTablet, film coated, extended release50 mg/1OralCarilion Materials Management2017-03-01Not applicableUs
DesvenlafaxineTablet, extended release100 mg/1OralAlembic Pharmaceuticals Limited2017-03-01Not applicableUs
DesvenlafaxineTablet, extended release25 mg/1OralActavis Pharma Company2017-03-01Not applicableUs
DesvenlafaxineTablet, film coated, extended release25 mg/1OralWest Ward Pharmaceutical2017-08-29Not applicableUs
DesvenlafaxineTablet, extended release50 mg/1OralBreckenridge Pharmaceutical, Inc.2015-07-13Not applicableUs
DesvenlafaxineTablet, extended release50 mg/1OralAlembic Pharmaceuticals Limited2017-03-01Not applicableUs
International/Other Brands
Pristiq / Zyven-OD
Categories
UNII
NG99554ANW
CAS number
93413-62-8
Weight
Average: 263.3752
Monoisotopic: 263.188529049
Chemical Formula
C16H25NO2
InChI Key
KYYIDSXMWOZKMP-UHFFFAOYSA-N
InChI
InChI=1S/C16H25NO2/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16/h6-9,15,18-19H,3-5,10-12H2,1-2H3
IUPAC Name
4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol
SMILES
CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1

Pharmacology

Indication

Desvenlafaxine is indicated for the treatment of major depressive disorder in adults.

Structured Indications
Pharmacodynamics

Desvenlafaxine is a selective serotonin and norepinephrine reuptake inhibitor. It lacks significant activity on muscarinic-cholinergic, H1-histaminergic, or α1-adrenergic receptors in vitro. Desvenlafaxine does not appear to exert activity against calcium, chloride, potassium and sodium ion channels and also lacks monoamine oxidase (MAO) inhibitory activity. It was also shown to lack significant activity again the cardiac potassium channel, hERG, in vitro. Compared to other SNRIs, desvenlafaxine undergoes simple metabolism, has a low risk of drug-drug interactions and does not have to be extensively titrated to reach a therapeutic dose. Some of the limitations of desvenlafaxine include moderate efficacy in the treatment of major depressive disorder, similar safety and tolerability profile to other SNRIs and possible transient discontinuation symptoms upon cessation of therapy.

Mechanism of action

Desvenlafaxine, the major active metabolite of venlafaxine, is a selective serotonin and norepinephrine reuptake inhibitor. The clinical effect of desvenlafaxine is thought to occur via potentiation of serotonin and norepinephrine in the central nervous system. Unlike venlafaxine, desvenlafaxine is thought to have a differential serotonergic and noradrenergic activity profile.

TargetActionsOrganism
ASodium-dependent serotonin transporter
inhibitor
Human
ASodium-dependent noradrenaline transporter
inhibitor
Human
Absorption

Absolute bioavailability is approximately 80% and is unaffected by food. Peak plasma concentration is reached in 7.5 hours.

Volume of distribution

3.4 L/kg, distribution into nonvascular compartments

Protein binding

~ 30%, protein binding is independent of drug concentration.

Metabolism

The primary route of metabolism is via conjugation mediated by UGT isoforms. Desvenlafaxine also undergoes oxidative N-demethylation via cytochrome P450 3A4 to a minor extent. CYP2D6 is not involved with the metabolism of desvenlafaxine.

Route of elimination

Excreted in the urine. Approximately 45% of the total oral dose is excreted unchanged in urine. Approximately 19% of the total oral dose is excreted as the glucuronide metabolite and < 5% is excreted as the oxidative metabolite, N,O-didesmethylvenlafaxine. Excreted in human milk.

Half life

The mean terminal half life is 11.1 hours and may be prolonged in patients with renal and/or moderate to severe hepatic impairment.

Clearance
Not Available
Toxicity

The safety and tolerability of desvenlafaxine is similar to other SNRIs. Common side effects upon initiation or dose increase include increased blood pressure and heart rate, agitation, tremor, sweating, nausea, headache, and sleep disturbances. May cause sexual dysfunction and weight loss in some patients. May cause increases in fasting serum total cholesterol, LDL cholesterol, and triglycerides. Withdrawal effects may occur and thus, the dose of desvenlafaxine should be titrated down prior to discontinuation.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Venlafaxine Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Desvenlafaxine.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Desvenlafaxine.Experimental
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Desvenlafaxine.Approved
AcenocoumarolThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Acenocoumarol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Desvenlafaxine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Desvenlafaxine.Approved
Acetylsalicylic acidDesvenlafaxine may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Desvenlafaxine.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Desvenlafaxine.Approved, Investigational
AlaproclateDesvenlafaxine may increase the serotonergic activities of Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Desvenlafaxine.Vet Approved
AlfentanilAlfentanil may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Desvenlafaxine.Investigational
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Desvenlafaxine.Experimental, Illicit
AlphaprodineAlphaprodine may increase the serotonergic activities of Desvenlafaxine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Desvenlafaxine.Approved, Illicit, Investigational
AlprenololThe serum concentration of Alprenolol can be increased when it is combined with Desvenlafaxine.Approved, Withdrawn
AmiodaroneThe metabolism of Desvenlafaxine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Desvenlafaxine.Approved, Investigational
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Desvenlafaxine.Approved, Illicit
AmoxapineDesvenlafaxine may increase the serotonergic activities of Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Desvenlafaxine.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Amphetamine.Approved, Illicit
AprepitantThe serum concentration of Desvenlafaxine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Desvenlafaxine.Approved, Investigational
ArotinololThe serum concentration of Arotinolol can be increased when it is combined with Desvenlafaxine.Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Desvenlafaxine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Desvenlafaxine.Approved
AtazanavirThe metabolism of Desvenlafaxine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Desvenlafaxine.Approved
AtomoxetineThe metabolism of Desvenlafaxine can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Desvenlafaxine.Investigational, Vet Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Desvenlafaxine.Illicit
BefunololThe serum concentration of Befunolol can be increased when it is combined with Desvenlafaxine.Experimental
BendroflumethiazideDesvenlafaxine may increase the hyponatremic activities of Bendroflumethiazide.Approved
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Desvenlafaxine.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Desvenlafaxine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Desvenlafaxine.Approved
BetaxololThe serum concentration of Betaxolol can be increased when it is combined with Desvenlafaxine.Approved
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Desvenlafaxine.Approved, Investigational
BevantololThe serum concentration of Bevantolol can be increased when it is combined with Desvenlafaxine.Approved
BezitramideBezitramide may increase the serotonergic activities of Desvenlafaxine.Experimental, Illicit, Withdrawn
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Desvenlafaxine.Approved
BoceprevirThe metabolism of Desvenlafaxine can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololThe serum concentration of Bopindolol can be increased when it is combined with Desvenlafaxine.Approved
BortezomibThe metabolism of Desvenlafaxine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Desvenlafaxine can be decreased when it is combined with Bosentan.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Desvenlafaxine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Desvenlafaxine.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Desvenlafaxine.Investigational
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Desvenlafaxine.Approved, Investigational, Withdrawn
BucindololThe serum concentration of Bucindolol can be increased when it is combined with Desvenlafaxine.Investigational
BufuralolThe serum concentration of Bufuralol can be increased when it is combined with Desvenlafaxine.Experimental, Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Desvenlafaxine.Approved, Investigational
BupranololThe serum concentration of Bupranolol can be increased when it is combined with Desvenlafaxine.Approved
BuprenorphineBuprenorphine may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit, Investigational, Vet Approved
BuspironeBuspirone may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Desvenlafaxine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Desvenlafaxine.Vet Approved
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Desvenlafaxine.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Desvenlafaxine.Approved, Illicit
ButorphanolButorphanol may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Desvenlafaxine.Investigational
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Desvenlafaxine.Approved, Investigational
CarfentanilCarfentanil may increase the serotonergic activities of Desvenlafaxine.Illicit, Investigational, Vet Approved
CarteololThe serum concentration of Carteolol can be increased when it is combined with Desvenlafaxine.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Desvenlafaxine.Approved, Investigational
CelecoxibDesvenlafaxine may increase the antiplatelet activities of Celecoxib.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Desvenlafaxine.Approved, Investigational
CeritinibThe serum concentration of Desvenlafaxine can be increased when it is combined with Ceritinib.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Desvenlafaxine.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Desvenlafaxine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Desvenlafaxine.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Desvenlafaxine.Approved
ChlorothiazideDesvenlafaxine may increase the hyponatremic activities of Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Desvenlafaxine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Desvenlafaxine.Approved, Investigational, Withdrawn
ChlorthalidoneDesvenlafaxine may increase the hyponatremic activities of Chlorthalidone.Approved
CimetidineThe metabolism of Desvenlafaxine can be decreased when combined with Cimetidine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Desvenlafaxine.Approved, Vet Approved
CitalopramDesvenlafaxine may increase the serotonergic activities of Citalopram.Approved
ClarithromycinThe metabolism of Desvenlafaxine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Desvenlafaxine can be decreased when combined with Clemastine.Approved
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Desvenlafaxine.Investigational
ClomipramineDesvenlafaxine may increase the serotonergic activities of Clomipramine.Approved, Vet Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Desvenlafaxine.Experimental
CloranololThe serum concentration of Cloranolol can be increased when it is combined with Desvenlafaxine.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Desvenlafaxine.Approved, Illicit
ClorindioneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Clorindione.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Desvenlafaxine.Experimental
ClotrimazoleThe metabolism of Desvenlafaxine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Desvenlafaxine.Approved
CobicistatThe metabolism of Desvenlafaxine can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Desvenlafaxine.Approved, Illicit
CodeineCodeine may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Desvenlafaxine.Approved, Investigational
CrizotinibThe metabolism of Desvenlafaxine can be decreased when combined with Crizotinib.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desvenlafaxine.Approved
CyclopenthiazideDesvenlafaxine may increase the hyponatremic activities of Cyclopenthiazide.Experimental
CyclosporineThe metabolism of Desvenlafaxine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe therapeutic efficacy of Desvenlafaxine can be decreased when used in combination with Cyproheptadine.Approved
DabrafenibThe serum concentration of Desvenlafaxine can be decreased when it is combined with Dabrafenib.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Desvenlafaxine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Desvenlafaxine.Investigational
DarunavirThe metabolism of Desvenlafaxine can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Desvenlafaxine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Desvenlafaxine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Desvenlafaxine can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Desvenlafaxine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Desvenlafaxine.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Desmopressin.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Desvenlafaxine.Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Desvenlafaxine.Approved, Vet Approved
DextromethorphanDesvenlafaxine may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideDextromoramide may increase the serotonergic activities of Desvenlafaxine.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit, Investigational, Withdrawn
DezocineDezocine may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Desvenlafaxine.Approved, Illicit, Vet Approved
DicoumarolThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Dicoumarol.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Desvenlafaxine.Experimental
DihydrocodeineDihydrocodeine may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit
DihydroergotamineThe metabolism of Desvenlafaxine can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Desvenlafaxine.Experimental, Illicit
DihydromorphineDihydromorphine may increase the serotonergic activities of Desvenlafaxine.Experimental, Illicit
DiltiazemThe metabolism of Desvenlafaxine can be decreased when combined with Diltiazem.Approved
DiphenadioneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Diphenadione.Experimental
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Desvenlafaxine.Approved
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Desvenlafaxine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Desvenlafaxine.Vet Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Desvenlafaxine.Approved
DoxycyclineThe metabolism of Desvenlafaxine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DPDPEDPDPE may increase the serotonergic activities of Desvenlafaxine.Experimental
DronedaroneThe metabolism of Desvenlafaxine can be decreased when combined with Dronedarone.Approved
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Desvenlafaxine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Desvenlafaxine.Experimental, Illicit
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Desvenlafaxine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Desvenlafaxine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Desvenlafaxine.Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Desvenlafaxine.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Desvenlafaxine.Approved, Investigational, Vet Approved
EnzalutamideThe serum concentration of Desvenlafaxine can be decreased when it is combined with Enzalutamide.Approved
EpanololThe serum concentration of Epanolol can be increased when it is combined with Desvenlafaxine.Experimental
ErythromycinThe metabolism of Desvenlafaxine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramDesvenlafaxine may increase the serotonergic activities of Escitalopram.Approved, Investigational
EsmololThe serum concentration of Esmolol can be increased when it is combined with Desvenlafaxine.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Desvenlafaxine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Desvenlafaxine.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Desvenlafaxine.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Desvenlafaxine.Approved, Illicit, Withdrawn
Ethyl biscoumacetateThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Desvenlafaxine.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Desvenlafaxine.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Desvenlafaxine.Approved, Illicit
EthylmorphineEthylmorphine may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Desvenlafaxine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Desvenlafaxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Desvenlafaxine.Approved
EtodolacDesvenlafaxine may increase the antiplatelet activities of Etodolac.Approved, Investigational, Vet Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Desvenlafaxine.Approved
EtoricoxibDesvenlafaxine may increase the antiplatelet activities of Etoricoxib.Approved, Investigational
EtorphineEtorphine may increase the serotonergic activities of Desvenlafaxine.Illicit, Vet Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Desvenlafaxine.Approved, Illicit, Withdrawn
FenfluramineDesvenlafaxine may increase the serotonergic activities of Fenfluramine.Illicit, Investigational, Withdrawn
FentanylFentanyl may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit, Investigational, Vet Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Desvenlafaxine.Experimental
FluconazoleThe metabolism of Desvenlafaxine can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Desvenlafaxine.Approved, Illicit
FluindioneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Fluindione.Investigational
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Desvenlafaxine.Approved, Illicit
FluoxetineDesvenlafaxine may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Desvenlafaxine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Desvenlafaxine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Desvenlafaxine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Desvenlafaxine.Approved, Investigational
FluvoxamineDesvenlafaxine may increase the serotonergic activities of Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Desvenlafaxine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Desvenlafaxine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Desvenlafaxine can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Desvenlafaxine.Approved, Illicit, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational, Vet Approved
Fusidic AcidThe serum concentration of Desvenlafaxine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Desvenlafaxine.Approved, Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Desvenlafaxine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Desvenlafaxine.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Desvenlafaxine.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Desvenlafaxine.Approved, Illicit
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Desvenlafaxine.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Desvenlafaxine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Desvenlafaxine.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Harmaline.Experimental
HeroinHeroin may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Desvenlafaxine.Approved
HydrochlorothiazideDesvenlafaxine may increase the hyponatremic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneHydrocodone may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit
HydroflumethiazideDesvenlafaxine may increase the hyponatremic activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneHydromorphone may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit
IdelalisibThe metabolism of Desvenlafaxine can be decreased when combined with Idelalisib.Approved
ImatinibThe metabolism of Desvenlafaxine can be decreased when combined with Imatinib.Approved
IndalpineDesvenlafaxine may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideDesvenlafaxine may increase the hyponatremic activities of Indapamide.Approved
IndenololThe serum concentration of Indenolol can be increased when it is combined with Desvenlafaxine.Withdrawn
IndinavirThe metabolism of Desvenlafaxine can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Desvenlafaxine.Investigational
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Desvenlafaxine.Approved, Investigational
Ioflupane I-123Desvenlafaxine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IproniazidIproniazid may increase the serotonergic activities of Desvenlafaxine.Withdrawn
IsavuconazoniumThe metabolism of Desvenlafaxine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Desvenlafaxine.Approved, Vet Approved
IsradipineThe metabolism of Desvenlafaxine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Desvenlafaxine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Desvenlafaxine can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Desvenlafaxine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Desvenlafaxine.Approved
KetobemidoneKetobemidone may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational
KetoconazoleThe metabolism of Desvenlafaxine can be decreased when combined with Ketoconazole.Approved, Investigational
L-TryptophanL-Tryptophan may increase the serotonergic activities of Desvenlafaxine.Approved, Nutraceutical, Withdrawn
LabetalolThe serum concentration of Labetalol can be increased when it is combined with Desvenlafaxine.Approved
LandiololThe serum concentration of Landiolol can be increased when it is combined with Desvenlafaxine.Investigational
LevobunololThe serum concentration of Levobunolol can be increased when it is combined with Desvenlafaxine.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Desvenlafaxine.Approved, Investigational
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational
LevomilnacipranDesvenlafaxine may increase the serotonergic activities of Levomilnacipran.Approved
LevorphanolLevorphanol may increase the serotonergic activities of Desvenlafaxine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Desvenlafaxine.Approved, Vet Approved
LinezolidLinezolid may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational
LithiumLithium may increase the serotonergic activities of Desvenlafaxine.Approved
LofentanilLofentanil may increase the serotonergic activities of Desvenlafaxine.Illicit
LopinavirThe metabolism of Desvenlafaxine can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Desvenlafaxine.Experimental
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Desvenlafaxine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Desvenlafaxine.Approved
LorpiprazoleThe serum concentration of Desvenlafaxine can be increased when it is combined with Lorpiprazole.Approved
LovastatinThe metabolism of Desvenlafaxine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Desvenlafaxine.Approved
LuliconazoleThe serum concentration of Desvenlafaxine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Desvenlafaxine can be increased when combined with Lumacaftor.Approved
LumiracoxibDesvenlafaxine may increase the antiplatelet activities of Lumiracoxib.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Desvenlafaxine.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Desvenlafaxine.Approved, Vet Approved
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Desvenlafaxine.Experimental
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Desvenlafaxine.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Desvenlafaxine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Desvenlafaxine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Desvenlafaxine.Approved, Investigational
MepindololThe serum concentration of Mepindolol can be increased when it is combined with Desvenlafaxine.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Desvenlafaxine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Desvenlafaxine.Approved, Illicit
MeptazinolMeptazinol may increase the serotonergic activities of Desvenlafaxine.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Desvenlafaxine.Approved, Investigational
MethadoneThe metabolism of Methadone can be decreased when combined with Desvenlafaxine.Approved
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Desvenlafaxine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Desvenlafaxine.Illicit, Withdrawn
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Desvenlafaxine.Approved
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Desvenlafaxine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Desvenlafaxine.Approved, Investigational, Vet Approved
MethyclothiazideDesvenlafaxine may increase the hyponatremic activities of Methyclothiazide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Desvenlafaxine.Experimental
Methylene blueDesvenlafaxine may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Desvenlafaxine.Approved
MetipranololThe serum concentration of Metipranolol can be increased when it is combined with Desvenlafaxine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Desvenlafaxine.Approved, Investigational
MetolazoneDesvenlafaxine may increase the hyponatremic activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Desvenlafaxine.Approved, Investigational
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Desvenlafaxine.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Desvenlafaxine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Desvenlafaxine.Approved, Illicit
MifepristoneThe serum concentration of Desvenlafaxine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranDesvenlafaxine may increase the serotonergic activities of Milnacipran.Approved
MinaprineMinaprine may increase the serotonergic activities of Desvenlafaxine.Approved
MitotaneThe serum concentration of Desvenlafaxine can be decreased when it is combined with Mitotane.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Desvenlafaxine.Approved
MorphineMorphine may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Desvenlafaxine.Approved, Investigational
NabumetoneDesvenlafaxine may increase the antiplatelet activities of Nabumetone.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Desvenlafaxine.Approved
NalbuphineNalbuphine may increase the serotonergic activities of Desvenlafaxine.Approved
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Desvenlafaxine.Approved, Investigational
NefazodoneThe metabolism of Desvenlafaxine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Desvenlafaxine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Desvenlafaxine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Desvenlafaxine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the serotonergic activities of Desvenlafaxine.Withdrawn
NicomorphineNicomorphine may increase the serotonergic activities of Desvenlafaxine.Experimental
NilotinibThe metabolism of Desvenlafaxine can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Desvenlafaxine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Desvenlafaxine.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Desvenlafaxine.Investigational
NormethadoneNormethadone may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit
OlanzapineDesvenlafaxine may increase the serotonergic activities of Olanzapine.Approved, Investigational
OlaparibThe metabolism of Desvenlafaxine can be decreased when combined with Olaparib.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Desvenlafaxine.Approved
OpiumOpium may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Desvenlafaxine.Investigational
OsimertinibThe serum concentration of Desvenlafaxine can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Desvenlafaxine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Desvenlafaxine.Approved, Investigational
OxprenololThe serum concentration of Oxprenolol can be increased when it is combined with Desvenlafaxine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Desvenlafaxine.Approved
OxycodoneOxycodone may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit, Investigational
OxymorphoneOxymorphone may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Desvenlafaxine can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Desvenlafaxine.Approved
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Desvenlafaxine.Approved, Investigational
ParecoxibDesvenlafaxine may increase the antiplatelet activities of Parecoxib.Approved
PargylinePargyline may increase the serotonergic activities of Desvenlafaxine.Approved
ParoxetineDesvenlafaxine may increase the serotonergic activities of Paroxetine.Approved, Investigational
PenbutololThe serum concentration of Penbutolol can be increased when it is combined with Desvenlafaxine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Desvenlafaxine.Experimental
PentazocinePentazocine may increase the serotonergic activities of Desvenlafaxine.Approved, Vet Approved
PentobarbitalThe metabolism of Desvenlafaxine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Desvenlafaxine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Desvenlafaxine.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Desvenlafaxine.Approved
PethidinePethidine may increase the serotonergic activities of Desvenlafaxine.Approved
PhenazocinePhenazocine may increase the serotonergic activities of Desvenlafaxine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Desvenlafaxine.Experimental
PhenindioneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Desvenlafaxine can be increased when combined with Phenobarbital.Approved
PhenoperidinePhenoperidine may increase the serotonergic activities of Desvenlafaxine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Desvenlafaxine.Approved
PhenprocoumonThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Phenprocoumon.Approved, Investigational
PhenytoinThe metabolism of Desvenlafaxine can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Desvenlafaxine.Approved
PindololThe serum concentration of Pindolol can be increased when it is combined with Desvenlafaxine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Desvenlafaxine.Approved, Investigational
PiritramidePiritramide may increase the serotonergic activities of Desvenlafaxine.Investigational
PirlindolePirlindole may increase the serotonergic activities of Desvenlafaxine.Approved
Platelet Activating FactorThe serum concentration of Platelet Activating Factor can be increased when it is combined with Desvenlafaxine.Experimental
PolythiazideDesvenlafaxine may increase the hyponatremic activities of Polythiazide.Approved
PosaconazoleThe metabolism of Desvenlafaxine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololThe serum concentration of Practolol can be increased when it is combined with Desvenlafaxine.Approved
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Desvenlafaxine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Desvenlafaxine.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Desvenlafaxine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Desvenlafaxine.Approved
PrimidoneThe metabolism of Desvenlafaxine can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Desvenlafaxine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Desvenlafaxine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Desvenlafaxine.Approved, Vet Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Desvenlafaxine.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Desvenlafaxine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Desvenlafaxine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Desvenlafaxine.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Desvenlafaxine.Approved, Investigational
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Desvenlafaxine.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Desvenlafaxine.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Desvenlafaxine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Desvenlafaxine.Approved
QuinethazoneDesvenlafaxine may increase the hyponatremic activities of Quinethazone.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Desvenlafaxine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Desvenlafaxine.Investigational
RanolazineThe metabolism of Desvenlafaxine can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilRemifentanil may increase the serotonergic activities of Desvenlafaxine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Desvenlafaxine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Desvenlafaxine.Approved, Investigational
RifabutinThe metabolism of Desvenlafaxine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Desvenlafaxine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Desvenlafaxine can be increased when combined with Rifapentine.Approved
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Desvenlafaxine.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Desvenlafaxine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Desvenlafaxine.Investigational
RofecoxibDesvenlafaxine may increase the antiplatelet activities of Rofecoxib.Investigational, Withdrawn
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Desvenlafaxine.Vet Approved
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Desvenlafaxine.Approved
RucaparibThe metabolism of Desvenlafaxine can be decreased when combined with Rucaparib.Approved, Investigational
SaquinavirThe metabolism of Desvenlafaxine can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Desvenlafaxine can be decreased when used in combination with Sarilumab.Approved
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Desvenlafaxine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Desvenlafaxine.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Desvenlafaxine.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Desvenlafaxine.Approved, Investigational, Withdrawn
SertralineDesvenlafaxine may increase the serotonergic activities of Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Desvenlafaxine.Approved, Vet Approved
SildenafilThe metabolism of Desvenlafaxine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Desvenlafaxine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Desvenlafaxine can be increased when it is combined with Simeprevir.Approved
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Desvenlafaxine.Approved
SotalolThe serum concentration of Sotalol can be increased when it is combined with Desvenlafaxine.Approved
St. John's WortThe serum concentration of Desvenlafaxine can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Desvenlafaxine can be increased when it is combined with Stiripentol.Approved
SufentanilSufentanil may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational
SulfisoxazoleThe metabolism of Desvenlafaxine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Desvenlafaxine.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Desvenlafaxine.Experimental
TalinololThe serum concentration of Talinolol can be increased when it is combined with Desvenlafaxine.Investigational
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Desvenlafaxine.Investigational
TapentadolTapentadol may increase the serotonergic activities of Desvenlafaxine.Approved
TelaprevirThe metabolism of Desvenlafaxine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Desvenlafaxine can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Desvenlafaxine.Approved
TertatololThe serum concentration of Tertatolol can be increased when it is combined with Desvenlafaxine.Experimental
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Desvenlafaxine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Desvenlafaxine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Desvenlafaxine.Investigational
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Desvenlafaxine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Desvenlafaxine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Desvenlafaxine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Desvenlafaxine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Desvenlafaxine.Approved, Investigational
TiclopidineThe metabolism of Desvenlafaxine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Desvenlafaxine.Vet Approved
TilidineTilidine may increase the serotonergic activities of Desvenlafaxine.Experimental
TimololThe serum concentration of Timolol can be increased when it is combined with Desvenlafaxine.Approved
TioclomarolThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Tioclomarol.Experimental
TocilizumabThe serum concentration of Desvenlafaxine can be decreased when it is combined with Tocilizumab.Approved
ToloxatoneToloxatone may increase the serotonergic activities of Desvenlafaxine.Approved
TramadolDesvenlafaxine may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Desvenlafaxine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Desvenlafaxine.Approved
TrazodoneDesvenlafaxine may increase the serotonergic activities of Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Desvenlafaxine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Desvenlafaxine.Vet Approved
TrichlormethiazideDesvenlafaxine may increase the hyponatremic activities of Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Desvenlafaxine.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Desvenlafaxine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Desvenlafaxine.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Desvenlafaxine.Approved, Vet Approved
ValdecoxibDesvenlafaxine may increase the antiplatelet activities of Valdecoxib.Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Desvenlafaxine.Approved, Investigational
VemurafenibThe serum concentration of Desvenlafaxine can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Desvenlafaxine.Experimental
VerapamilThe metabolism of Desvenlafaxine can be decreased when combined with Verapamil.Approved
VilazodoneDesvenlafaxine may increase the serotonergic activities of Vilazodone.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Desvenlafaxine.Experimental
VoriconazoleThe metabolism of Desvenlafaxine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineDesvenlafaxine may increase the serotonergic activities of Vortioxetine.Approved
WarfarinThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Warfarin.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Desvenlafaxine.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Desvenlafaxine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Desvenlafaxine.Approved, Illicit, Investigational
ZimelidineDesvenlafaxine may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Desvenlafaxine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Desvenlafaxine.Vet Approved
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Desvenlafaxine.Approved
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Desvenlafaxine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Desvenlafaxine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Desvenlafaxine.Approved, Investigational
Food Interactions
  • Take without regard to meals.

References

Synthesis Reference

Karel Pospisilik, Lambertus Thijs, "Process for making desvenlafaxine." U.S. Patent US20070299283, issued December 27, 2007.

US20070299283
General References
  1. Ilett KF, Watt F, Hackett LP, Kohan R, Teoh S: Assessment of infant dose through milk in a lactating woman taking amisulpride and desvenlafaxine for treatment-resistant depression. Ther Drug Monit. 2010 Dec;32(6):704-7. doi: 10.1097/FTD.0b013e3181f88f70. [PubMed:20926994]
  2. Kamath J, Handratta V: Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. Expert Rev Neurother. 2008 Dec;8(12):1787-97. doi: 10.1586/14737175.8.12.1787. [PubMed:19086875]
  3. Kornstein SG, Jiang Q, Reddy S, Musgnung JJ, Guico-Pabia CJ: Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry. 2010 Aug;71(8):1088-96. doi: 10.4088/JCP.10m06018blu. [PubMed:20797382]
  4. Liebowitz MR, Tourian KA: Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials. Prim Care Companion J Clin Psychiatry. 2010;12(3). pii: PCC.09r00845. doi: 10.4088/PCC.09r00845blu. [PubMed:20944767]
  5. Mason JN, Deecher DC, Richmond RL, Stack G, Mahaney PE, Trybulski E, Winneker RC, Blakely RD: Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter. J Pharmacol Exp Ther. 2007 Nov;323(2):720-9. Epub 2007 Aug 2. [PubMed:17673606]
  6. Montgomery SA, Fava M, Padmanabhan SK, Guico-Pabia CJ, Tourian KA: Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder. Int Clin Psychopharmacol. 2009 Nov;24(6):296-305. doi: 10.1097/YIC.0b013e32832fbb5a. [PubMed:19779354]
  7. Oganesian A, Shilling AD, Young-Sciame R, Tran J, Watanyar A, Azam F, Kao J, Leung L: Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities. Psychopharmacol Bull. 2009;42(2):47-63. [PubMed:19629022]
  8. Pae CU, Park MH, Marks DM, Han C, Patkar AA, Masand PS: Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause. Curr Opin Investig Drugs. 2009 Jan;10(1):75-90. [PubMed:19127490]
  9. Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ: Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. Curr Med Res Opin. 2010 Jan;26(1):139-50. doi: 10.1185/03007990903408678. [PubMed:19919295]
  10. Pae CU: Desvenlafaxine in the treatment of major depressive disorder. Expert Opin Pharmacother. 2011 Dec;12(18):2923-8. doi: 10.1517/14656566.2011.636033. [PubMed:22098230]
  11. Preskorn S, Patroneva A, Silman H, Jiang Q, Isler JA, Burczynski ME, Ahmed S, Paul J, Nichols AI: Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol. 2009 Feb;29(1):39-43. doi: 10.1097/JCP.0b013e318192e4c1. [PubMed:19142106]
  12. Link [Link]
External Links
Human Metabolome Database
HMDB0015646
KEGG Drug
D02570
PubChem Compound
125017
PubChem Substance
99443254
ChemSpider
111300
BindingDB
86748
ChEBI
83527
ChEMBL
CHEMBL1118
PharmGKB
PA165958374
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Desvenlafaxine
ATC Codes
N06AX23 — Desvenlafaxine
AHFS Codes
  • 28:16.04.16 — Selective Serotonin and Norepinephrine-reuptake Inhibitors
FDA label
Download (379 KB)
MSDS
Download (86.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceMajor Depressive Disorder (MDD)1
1CompletedOtherHealthy Volunteers3
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentMajor Depressive Disorder (MDD)3
1Unknown StatusBasic ScienceHealthy Volunteers1
1WithdrawnOtherHepatic Impairment1
2Active Not RecruitingTreatmentChronic Hepatitis C Virus (HCV) Infection1
2CompletedTreatmentMajor Depressive Disorder (MDD)1
2, 3TerminatedTreatmentCancers / Cardiovascular Disease (CVD) / Diabetes Mellitus (DM) / Major Depressive Disorder (MDD)1
3CompletedTreatmentDepression1
3CompletedTreatmentMajor Depressive Disorder (MDD)5
3Unknown StatusTreatmentMajor Depressive Disorder (MDD) / Menopausal Staging and Vasomotor Symptoms (for Females)1
4CompletedBasic ScienceCYP3A4 Protein, Human / Cytochrome P-450 CYP2D6 / Pharmacokinetics1
4CompletedOtherHealthy Controls / Major Depressive Disorder (MDD)1
4CompletedTreatmentChronic Depressive Disorder / Dysthymic Disorder1
4CompletedTreatmentDepression / Methadone Treatment / Opioid Dependence1
4CompletedTreatmentMajor Depressive Disorder (MDD)2
4CompletedTreatmentSocial Anxiety Disorder (SAD)1
4Not Yet RecruitingTreatmentMenopausal Hot Flushes / Neoplasms, Breast1
4RecruitingOtherAnhedonia / Depression1
4RecruitingTreatmentGeneralized Anxiety Disorder (GAD)1
4RecruitingTreatmentVascular Depression1
4TerminatedNot AvailableMajor Depressive Disorder (MDD) / Vasomotor Symptoms1
4Unknown StatusBasic ScienceMajor Depressive Disorder (MDD)1
4Unknown StatusTreatmentMajor Depressive Disorder (MDD)1
Not AvailableCompletedNot AvailableAcute Kidney Injury (AKI) / Depression1
Not AvailableCompletedTreatmentDysthymic Disorder1
Not AvailableCompletedTreatmentMajor Depressive Disorder (MDD)1
Not AvailableEnrolling by InvitationNot AvailableBipolar Disorder (BD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Tablet, film coated, extended releaseOral25 mg/1
Tablet, film coated, extended releaseOral100 mg/1
Tablet, film coated, extended releaseOral50 mg/1
Tablet, extended releaseOral100 mg
Tablet, extended releaseOral50 mg
Tablet, extended releaseOral100 mg/1
Tablet, extended releaseOral25 mg/1
Tablet, extended releaseOral50 mg/1
Prices
Unit descriptionCostUnit
Pristiq 100 mg extended-release tablet4.46USD tablet
Pristiq 50 mg extended-release tablet4.31USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2436668No2009-05-262022-02-11Canada
US6673838No2002-03-012022-03-01Us
US8269040No2007-07-052027-07-05Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilitySoluble FDA label
logP0.21FDA label
Predicted Properties
PropertyValueSource
Water Solubility1.4 mg/mLALOGPS
logP2.6ALOGPS
logP2.29ChemAxon
logS-2.3ALOGPS
pKa (Strongest Acidic)10.11ChemAxon
pKa (Strongest Basic)8.87ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area43.7 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity78.54 m3·mol-1ChemAxon
Polarizability30.29 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9772
Blood Brain Barrier+0.7722
Caco-2 permeable+0.8404
P-glycoprotein substrateSubstrate0.6918
P-glycoprotein inhibitor INon-inhibitor0.7835
P-glycoprotein inhibitor IIInhibitor0.5921
Renal organic cation transporterNon-inhibitor0.5894
CYP450 2C9 substrateNon-substrate0.7837
CYP450 2D6 substrateSubstrate0.7753
CYP450 3A4 substrateSubstrate0.6997
CYP450 1A2 substrateNon-inhibitor0.6816
CYP450 2C9 inhibitorNon-inhibitor0.757
CYP450 2D6 inhibitorInhibitor0.6334
CYP450 2C19 inhibitorNon-inhibitor0.7811
CYP450 3A4 inhibitorNon-inhibitor0.8646
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8888
Ames testNon AMES toxic0.8084
CarcinogenicityNon-carcinogens0.7648
BiodegradationNot ready biodegradable0.9927
Rat acute toxicity2.4429 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6046
hERG inhibition (predictor II)Inhibitor0.5603
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-03di-0090000000-90abc876cc91a398d25d
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-03y0-0960000000-0219d7d7ea1a46c8cfdf
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-014i-0900000000-529d7fb237a99866f0b4
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-0090000000-ccb6c8906a1ac7d27cd6
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0290000000-422a5daa0d4bf51308ef
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001i-0910000000-03ecfc411d730c35b892
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001i-0900000000-d0fa1892dfaae0510ee8
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001m-0900000000-7515704132219cf15c78
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0090000000-1a8bdddd358a8706e896
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0090000000-c218ef4ab652831ee930
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-06r2-4090000000-b1767a9c9c01cb43bca9
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-9320000000-e38b2ae07ab3cc9b7693
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-9600000000-edbb26312a47b22bffb7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-9800000000-b41801091e3c7132fec9
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-9800000000-4b30d7e9d71dab81d9d7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0090000000-5e859f484b6e3a5560c4
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-06r2-4090000000-ef1215dc6fc4eb904b90
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-9310000000-dac7bd983af34469bc5f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-9600000000-8ea073e198c8a9a9a528
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-9800000000-f8db755a9bb1f788394e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-9700000000-b50718dbaca8fdae5401
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0090000000-7ed75e3f487ccd4f981d
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0bta-6090000000-c41286a6446e8e51aab6
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-9100000000-e80f225fbf61adb457b7
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-9200000000-81250c46509f91e0409b
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-9400000000-b6e08db8ef3bea2640a3
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-9500000000-6ece9a9beebd1cd99bfd
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-9400000000-5411c26ee28734211eb5
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-2090000000-134bece44509731dae98
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-9150000000-383ebf283bfe27d5b20f

Taxonomy

Description
This compound belongs to the class of organic compounds known as cyclohexanols. These are compounds containing an alcohol group attached to a cyclohexane ring.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Alcohols and polyols
Direct Parent
Cyclohexanols
Alternative Parents
Aralkylamines / 1-hydroxy-2-unsubstituted benzenoids / Benzene and substituted derivatives / Tertiary alcohols / 1,3-aminoalcohols / Trialkylamines / Cyclic alcohols and derivatives / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
1-hydroxy-2-unsubstituted benzenoid / Cyclohexanol / Phenol / Aralkylamine / Monocyclic benzene moiety / Benzenoid / 1,3-aminoalcohol / Cyclic alcohol / Tertiary alcohol / Tertiary amine
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
tertiary amino compound, phenols, cyclohexanols (CHEBI:83527)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M, Andree TH: Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006 Aug;318(2):657-65. Epub 2006 May 4. [PubMed:16675639]
  2. Mason JN, Deecher DC, Richmond RL, Stack G, Mahaney PE, Trybulski E, Winneker RC, Blakely RD: Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter. J Pharmacol Exp Ther. 2007 Nov;323(2):720-9. Epub 2007 Aug 2. [PubMed:17673606]
  3. Perry R, Cassagnol M: Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder. Clin Ther. 2009 Jun;31 Pt 1:1374-404. doi: 10.1016/j.clinthera.2009.07.012. [PubMed:19698900]
  4. Kamath J, Handratta V: Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. Expert Rev Neurother. 2008 Dec;8(12):1787-97. doi: 10.1586/14737175.8.12.1787. [PubMed:19086875]
  5. Liebowitz MR, Tourian KA: Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials. Prim Care Companion J Clin Psychiatry. 2010;12(3). pii: PCC.09r00845. doi: 10.4088/PCC.09r00845blu. [PubMed:20944767]
  6. Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ: Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. Curr Med Res Opin. 2010 Jan;26(1):139-50. doi: 10.1185/03007990903408678. [PubMed:19919295]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M, Andree TH: Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006 Aug;318(2):657-65. Epub 2006 May 4. [PubMed:16675639]
  2. Mason JN, Deecher DC, Richmond RL, Stack G, Mahaney PE, Trybulski E, Winneker RC, Blakely RD: Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter. J Pharmacol Exp Ther. 2007 Nov;323(2):720-9. Epub 2007 Aug 2. [PubMed:17673606]
  3. Perry R, Cassagnol M: Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder. Clin Ther. 2009 Jun;31 Pt 1:1374-404. doi: 10.1016/j.clinthera.2009.07.012. [PubMed:19698900]
  4. Kamath J, Handratta V: Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. Expert Rev Neurother. 2008 Dec;8(12):1787-97. doi: 10.1586/14737175.8.12.1787. [PubMed:19086875]
  5. Liebowitz MR, Tourian KA: Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials. Prim Care Companion J Clin Psychiatry. 2010;12(3). pii: PCC.09r00845. doi: 10.4088/PCC.09r00845blu. [PubMed:20944767]
  6. Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ: Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. Curr Med Res Opin. 2010 Jan;26(1):139-50. doi: 10.1185/03007990903408678. [PubMed:19919295]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Pae CU: Desvenlafaxine in the treatment of major depressive disorder. Expert Opin Pharmacother. 2011 Dec;12(18):2923-8. doi: 10.1517/14656566.2011.636033. [PubMed:22098230]

Drug created on May 06, 2010 10:22 / Updated on January 21, 2018 04:16